ArticleBritish journal of clinical pharmacology2022

Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients.

Charlotte D C C van der Heijden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.